In recent years, immune checkpoint inhibitors have shown promising therapeutic efficacy in locally advanced solid tumors beyond ESCC when combined with chemoradiotherapy with programmed cell death 1 (PD-1) blockade as first-line treatment [13, 14]. Here, PDCD1 is linked to esophageal squamous cell carcinoma.